Evidence map›Paper›PMID 42432400›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2026

RNF149/RBM25/MYC/PD-L1 axis promotes CD8

Xuefei Liu, Xingming Qu, Yuanhua Zou, Yu Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xuefei Liu *Department of Oncology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.
Xingming Qu *Military Clinic, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.
Yuanhua ZouGraduate School of China Medical University, Shenyang, People's Republic of China.
Yu ChenDepartment of Urology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China. mnwkcy1024@163.com.

Funding

Liaoning Province Science and Technology Plan Joint Project 2024-MSLH-535
6 · The paper itself

Abstract

backgroundRenal cell carcinoma (RCC) is a common kidney cancer, and clear cell RCC (ccRCC) represents the most common pathological type. CD8

methodsThe expression of RNF149 in clinical ccRCC specimens was determined with western blot and immunohistochemistry staining, and the overexpression or knockdown of RNF149 in ccRCC cells were realized via lentivirus infection. CD8

resultsRNF149 was upregulated in ccRCC specimens, compared with the para-carcinoma normal kidney tissues, and its expression was associated with tumor size and TNM stage. Gain- and loss-of-function experiments revealed that RNF149 promoted the colony formation, and inhibited apoptosis of ccRCC cells, in the presence of co-culture with CD8

conclusionRNF149 promoted ccRCC growth in vivo and in vitro, and induced CD8

Indexed as

B7-H1 AntigenCarcinoma, Renal CellCD8-Positive T-LymphocytesKidney NeoplasmsProto-Oncogene Proteins c-mycTumor MicroenvironmentUbiquitin-Protein LigasesAnimalsCell Line, TumorFemaleHumansMaleMiceMice, Inbred BALB CMice, NudeMiddle AgedB7-H1 AntigenCD274 protein, humanProto-Oncogene Proteins c-mycUbiquitin-Protein LigasesCD8+ T cellsClear cell renal cell carcinomaPD-L1RBM25RNF149

Identifiers

PMID42432400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.